CARLSBAD, Calif. June 14, 2012- International Stem Cell
Corporation (OTCBB: ISCO) www.internationalstemcell.com announced that scientists in its
wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a
technology to modify human stem cells by using engineered proteins, called
"transducible transcription factors" or "TTFs". TTFs are designed to pass into stem cells and
direct the stem cells to change into specific cell types that can be both
therapeutically-useful and can be used as revenue-generating research products.
In contrast to more traditional cell therapy methods this
technology does not require the use of viruses or chemicals, and has the
potential to produce safe therapeutic cells from stem cells. In addition, the TTF proteins are naturally
eliminated by the cells when no longer required, a characteristic that further
improves safety. The Company intends
that this technology, once perfected, will first be used to create
revenue-generating research products for sale through Lifeline Cell
Technology’s international distribution channels to the academic, biotechnology
and pharmaceutical markets for cellular proteins, including the quickly growing
markets for the study of stem cell biology and drug testing.
According to Jeffrey Janus, Lifeline Cell Technology’s CEO, “These
proteins can be sold into the market for cellular proteins which exceeds $700
million and represents an excellent opportunity for LCT to grow sales. Since the technology also has broad
application in research and therapy, it should provide ISCO with future
out-licensing opportunities to the biotechnology and pharmaceutical
industries.”
Forward-looking Statements
Statements pertaining
to anticipated developments, the potential benefits of research programs and
products, and other opportunities for the company and its subsidiaries, along
with other statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes,"
"plans," "anticipates," "expects,"
"estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, regulatory approvals, need and ability
to obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties
that affect the company's business, particularly those mentioned in the
cautionary statements found in the company's Securities and Exchange Commission
filings. The company disclaims any intent or obligation to update
forward-looking statements.
To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
